1. Home
  2. RRX vs CYTK Comparison

RRX vs CYTK Comparison

Compare RRX & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Regal Rexnord Corporation

RRX

Regal Rexnord Corporation

HOLD

Current Price

$209.28

Market Cap

13.6B

Sector

N/A

ML Signal

HOLD

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$66.44

Market Cap

7.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RRX
CYTK
Founded
1955
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
7.6B
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
RRX
CYTK
Price
$209.28
$66.44
Analyst Decision
Buy
Strong Buy
Analyst Count
10
19
Target Price
$209.70
$89.26
AVG Volume (30 Days)
941.2K
1.7M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
0.67%
N/A
EPS Growth
42.86
N/A
EPS
4.20
N/A
Revenue
$3,257,100,000.00
$13,368,000.00
Revenue This Year
$4.15
$6.88
Revenue Next Year
$12.25
$308.26
P/E Ratio
$49.58
N/A
Revenue Growth
5.21
N/A
52 Week Low
$94.42
$29.31
52 Week High
$229.30
$70.98

Technical Indicators

Market Signals
Indicator
RRX
CYTK
Relative Strength Index (RSI) 61.80 59.02
Support Level $136.55 $59.12
Resistance Level $227.65 $69.48
Average True Range (ATR) 8.13 2.30
MACD 3.16 0.31
Stochastic Oscillator 97.89 78.72

Price Performance

Historical Comparison
RRX
CYTK

About RRX Regal Rexnord Corporation

Regal Rexnord Corp is in the engineering and manufacturing of industrial powertrain solutions, power transmission components, electric motors, electronic controls, air-moving products, and specialty electrical components and systems, serving customers around the world. The three operating segments include Automation & Motion Control (AMC) segment; Industrial Powertrain Solutions (IPS) segment, which derives maximum revenue; and Power Efficiency Solutions (PES) segment. Geographically, the company operates in North America, Europe, Asia, and Rest of the world, of which it derives maximum revenue from North America.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: